Abstract
The use of T cells with chimeric antigen receptors (CAR-T) has revolutionized the treatment of hematologic malignancies. However, applying this approach to solid tumors faces technical challenges, such as the inefficient infiltration of these cells into the tumor microenvironment and the immunosuppressive environment encountered in these tumors. Molecular profiles of CAR-T cells associate…